KBY Biotech Indexv0.0.34
Search
← Pipeline|CAM-IIT-240

CAM-IIT-240

NDA/BLA
By CAMS
Source: Trial-derived·Trials: 1
Modality
Gene Editing
MOA
RAS(ON)i
Target
AHR
Pathway
Lipid Met
ET
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
~May 2021
→ ~Aug 2022
Phase 2
~Nov 2022
→ ~Feb 2024
Phase 3
~May 2024
→ ~Aug 2025
NDA/BLA
Nov 2025
→ Jul 2025
NDA/BLACurrent
NCT08933571
1,843 pts·ET
2025-11→2025-07·Completed
1,843 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-178mo agoPh3 Readout· ET
Trial Timeline
Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2025-07-17 · 8mo ago
ET
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT08933571NDA/BLAETCompleted1843ACR20
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-2901PfizerPhase 2AHRSOS1i
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
AZN-1715AstraZenecaPhase 3AHRFXIai
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
BAY-6520BayerPhase 2AHRTROP-2 ADC
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
SemasacituzumabJazz PharmaPhase 2AHRAuroraAi
180-3597Innovent BioPreclinicalSHP2RAS(ON)i